Psychedelics Weekly – Research Explained: Ket...

Fireside Project is a nonprofit that helps reduce the risks of psychedelic experiences through a free support line, coaching, education, and research. In this episode, Joshua White speaks with Psychedelics Today about why real-time support matters, what it takes to run a national ...  Show more

Manvir Singh joins Psychedelics Today to unpack what shamanism means and why the term matters now. Singh is an anthropologist and author of Shamanism: The Timeless Religion. He argues that shamanism is not limited to "remote" societies or the past. Instead, it reliably reappears ...  Show more

Psychiatrist and psychedelics and bipolar researcher Dr. Josh Woolley (University of California San Francisco), and peer researcher Amir speak on psilocybin, ketamine, and psychedelics and their links with bipolar disorder, and what the science says about psychedelics as treat ...

This episode I discuss medical research on psychedelic compounds with Dr. Matthew Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine. We discuss the biology and medical clinical-trial uses of psilocybin, MDMA, ayahuasca, DMT, and L ...  Show more

We’re in the midst of a psychedelic renaissance, where this once demonized class of drugs is now front and center receiving attention among entrepreneurs, investors, clinical trials and even patients. In this special conversation, TED Health’s Dr. Shoshana Ungerleider speaks with ...  Show more

Dr. Paul Liknaitsky is the head of clinical psychedelic research at Monash University Australia. He is conducting world-first clinical trials into the use of magic mushrooms and ecstasy to treat depression, anxiety, and PTSD. This is his second time on this podcast to chat about ...  Show more